Experimental evidence for the beneficial effects on heart failure of chronic treatment with
ACE inhibitors accumulated from early 1980 in experimental models of LV dysfunction …

Ischemic heart disease is the principal etiology of heart failure in the Western world.
Myocardial ischemia is important in cardiac remodeling, a process that leads to a …

The development of angiotensin-converting enzyme inhibitors (ACE inhibitors) has been
one of the most remarkable stories in the treatment of cardiovascular diseases. Angiotensin …

Any new therapeutic advance requires clear proof of effectiveness from well-designed and
well-conducted clinical trials that establish both the range of anticipated benefits and the …

Angiotensin-converting enzyme inhibitors improve endothelial function, inhibit experimental
atherogenesis, and decrease ischemic events. The Quinapril Ischemic Event Trial was …

This paper reports the rationale for the cardiovascular protective effects of ACE inhibitors
(ACEI) and reviews the overall results of recent randomized clinical trials. ACEI improve the …

The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an
8,100 patient, randomized, double-blind, placebo-controlled trial designed to determine the …

At a time when deaths from coronary heart disease and stroke are markedly declining,
mortality from heart failure is increasing. Heart failure is a costly and devastating disease …

Proven cardiovascular benefit from angiotensin-converting enzyme (ACE) inhibition is a
cornerstone of evidence-based medicine. The first study to show dramatic benefits from ACE …

Left ventricular (LV) function and survival can be improved with captopril when initiated later
than 24 hours after acute myocardial infarction. Animal studies suggest additional benefits …